New Zealand markets close in 4 hours 43 minutes

OCGN Jan 2023 7.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
As of 09:34AM EDT. Market open.
Full screen
Previous close0.2500
Open0.2200
Bid0.1100
Ask0.3000
Strike7.50
Expiry date2023-01-20
Day's range0.2200 - 0.2500
Contract rangeN/A
Volume12
Open interest4.07k
  • Motley Fool

    Is Ocugen Finally on the Way to Vaccine Revenue?

    Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.

  • Motley Fool

    Where Will Ocugen Be in 1 Year?

    The past 18 months have been a roller coaster for Ocugen (NASDAQ: OCGN). Shares of the biotech company skyrocketed in early 2021 after it announced an agreement with India-based Bharat Biotech. The deal stipulated that Ocugen would hold the right to commercialize the Covaxin coronavirus vaccine, which was originally developed by Bharat Biotech, in the U.S. and Canada.

  • Motley Fool

    Ocugen, Inc. (OCGN) Q1 2022 Earnings Call Transcript

    With me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide a financial update. Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022.